MiNK Therapeutics, Inc. (INKT) Misses Q4 EPS by 1c

MiNK Therapeutics, Inc. (NASDAQ: INKT) reported Q4 EPS of ($0.16), $0.01 worse than the analyst estimate of ($0.15).

For earnings history and earnings-related data on MiNK Therapeutics, Inc. (INKT) click here.

You May Also Be Interested In

• Activist investor presses Xerox to review financial services arm - Bloomberg
• Braze, Inc. (BRZE) Tops Q2 EPS by 4c; offers guidance
• Barnes & Noble Education (BNED) Tops Q1 EPS by 12c